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Background. The role of vitamin D in the body’s ability to ﬁght inﬂuenza and URI’s may be dependent on regulation of speciﬁc
cytokines that participate in the host inﬂammatory response. The aim of this study was to test the hypothesis that vitamin D
can inﬂuence intracellular signaling to regulate the production of cytokines. Subjects and Methods. This study was a 3-month
prospective placebo-controlled trial of vitamin D3 supplementation in ambulatory adults [Li-Ng et al., 2009]. 162 volunteers
were randomized to receive either 50μg/d (2000 IU) of vitamin D3 or matching placebo. 25(OH)D and the levels of 10 diﬀerent
cytokines(IL-2,4,5,6,8,10,13,GM-CSF,IFN-γ,TNF -α)weremeasuredintheserumofparticipantsatbaselineandtheﬁnalvisit.
There were 6 drop-outs from the active vitamin D group and 8 from the placebo group. Results. In the active vitamin D group, we
found a signiﬁcant median percent decline in levels of GM-CSF (−62.9%, P<. 0001), IFN-γ (−38.9%, P<. 0001), IL-4 (−50.8%,
P = .001), IL-8 (−48.4%, P<. 0001), and IL-10 (−70.4%, P<. 0001). In the placebo group, there were signiﬁcant declines for
GM-CSF (−53.2%, P = .0007) and IFN-γ (−34.4%, P = .0011). For each cytokine, there was no signiﬁcant diﬀerence in the rate
of decline between the two groups. 25(OH)D levels increased in the active vitamin D group from a mean of 64.3 ±25.4nmol/L to
88.5 ± 23.2nmol/L. Conclusions. The present study did not show that vitamin D3 supplementation changed circulating cytokine
levels among healthy adults.
1.Introduction
VitaminDisproducedintheskinwhensunlightisabsorbed.
Thus, vitamin D levels, or serum 25-hydroxyvitamin D
(25(OH)D), ﬂuctuate seasonally. 25(OH)D levels are low
during the winter in northern latitudes because of decreased
amounts of sunlight. A conventional diet usually does
not provide adequate amounts of vitamin D. Vitamin D
insuﬃciency results in a number of skeletal and extraskele-
tal complications. It has been associated with decreased
muscle strength [1], breast cancer [2, 3], colon cancer
[4], cardiovascular disease [5], and autoimmune disorders
such as type 1 diabetes [6], rheumatoid arthritis [7]a n d
systemic lupus erythematosus [7]. Based on vitamin D’s
role in the basic innate immune defense mechanisms, it
has been suggested as an adjuvant treatment of tuberculosis
[8]. Levels of 25(OH)D, below 17.8ng/ml are associated
with a 26% increased risk of all-cause mortality in the
general population even after adjusting for known CVD
risk factors, socioeconomic status, and other characteristics
[9].
In vitro and in vivo studies show a role for vitamin
D as an important component of the innate immune
system. The innate immune system provides front-line
protection against infectious agents. Expression of vitamin
Dr e c e p t o ro c c u r si nd i ﬀerent cells of the myeloid and
lymphoid lineage. The active form of vitamin D, 1,25-
dihydroxyvitamin D (1,25(OH)2D), increases the produc-
tion of endogenous antibiotics called antimicrobial peptides
(AMP) in human monocytes, neutrophils, and epithelial
cells [10]. AMPs such as defensin and cathelicidin have a
broad range of actions against microorganisms, including
bacteria,fungi,andviruses.Liuetal.showedthatstimulation
of toll-like receptors (TLR) 2/1 engages a vitamin D-
dependent intracellular circuit that results in the expression
of cathelicidin, enhancing the microbicidal capability of the
monocyte [8]. Remarkably, the authors also observed that
sera from African-American individuals, who are known2 International Journal of Endocrinology
to have substantially lower serum 25(OH)D levels than
whites [11], were ineﬃcient in inducing genetic expression
of cathelicidin. When the sera was supplemented with
25(OH)D, cathelicidin levels increased to levels observed in
monocytes collected from whites. This suggests that vitamin
D insuﬃciency during the winter may increase susceptibility
to infections, particularly viral respiratory infections.
It is estimated that 72% of adults experience at least
one URI per year and those adults experience an average of
2.5 URIs per year [12]. Every year 5% to 20% of the U.S.
population get the ﬂu [13]. Vitamin D may also play a role in
reducing the severity of URI symptoms by regulating speciﬁc
cytokinesthatparticipate in thehostinﬂammatoryresponse.
Vitamin D’s role in ﬁghting inﬂuenza may be dependent
on suppression of pro-inﬂammatory cytokines Interferon
gamma, TNF-α, and IL-12 in the macrophage [14].
1,25(OH)2D has been shown to inhibit mononuclear
and T lymphocyte cell proliferation by decreasing the
production of IL-1β,I L - 2 ,I L - 6 ,i n t e r f e r o nγ (IFN-γ), and
TNF-α [15]. A randomized controlled trial by Schleithoﬀ
et al. showed that 50μg/day (2000 IU/day) of vitamin D3
reduced the inﬂammatory milieu in CHF patients [16].
1,25(OH)2D may play a protective role against inﬂam-
matory bowel disease as was shown in a mouse model
of colitis. Tissue-speciﬁc alterations in the expression of
cytokines IL-1β, IL-10, and IL-17 were demonstrated in
Cyp27b1 knockout mice [17].
When reviewing the adverse events from our prior study
of vitamin D3 supplementation in postmenopausal African
American women [18], we noticed a signiﬁcant diﬀerence in
the reported incidence of URI symptoms between the active
vitamin D group and the placebo group. This ﬁnding led us
to conclude that higher doses of vitamin D supplementation
may protect against viral URI’s [19].
CurrentrecommendationsforvitaminDintakearebased
on amounts required to sustain optimal skeletal health.
Schleithoﬀ’s study and our prior study suggest that optimal
function of the innate immune system might require higher
doses of vitamin D. In this study, we administered 50μg/day
(2000 IU) of vitamin D3 which is the tolerable upper intake
level (UL) for vitamin D for children and adults set by the
Food and Nutrition Board of the Institute of Medicine [20].
Experts in the U.S. believe that higher intakes of vitamin D
are necessary and that these higher intakes are safe [21, 22].
The role of vitamin D in the body’s ability to ﬁght
inﬂuenza and URI’s may be dependent on regulation of
speciﬁc cytokines that participate in the host inﬂammatory
response.Theaimofthisstudywastotestthehypothesisthat
vitaminDcaninﬂuenceintracellularsignalingtoregulatethe
production of cytokines. The levels of 10 diﬀerent cytokines
produced by T cells (Th1, Th2, regulatory T cells, NK cells)
andmacrophagesweremeasuredintheserumofparticipants
at baseline and the ﬁnal visit.
2. Patientsand Methods
2.1. Subjects. Study participants were recruited from the
Long Island, New York community (latitude, 40.7 degrees
N) between December 2006 and March 2007 (Figure 1
Flowchart). Volunteers were recruited from local newspaper
advertisements, mailing of brochures to community resi-
dents, and ﬂyers posted at Winthrop University Hospital
medical oﬃces. Patients were eligible for the study if they
met the following criteria: ambulatory adult age 18–80 and
stable medical condition with no change in medications for
6 months prior to study entry. Exclusion criteria included
morbid obesity (body mass index >35kg/m2); current
tobacco use; history of hypercalcemia, nephrolithiasis or
sarcoidosis; pregnancy; recent hospitalization; current liver
or kidney disorders, malignancy and malabsorption; and
use of immunosuppressants or medications that interfere
with vitamin D metabolism such as phenytoin and carba-
mazepine. Race determination was by self-declaration. All
participants provided written informed consent and the trial
was approved by the institutional review board of Winthrop
University Hospital. The results of this study have been
recently reported [19].
2.2. Study Design. This study was a 3-month prospec-
tive, randomized, double-blind, placebo-controlled trial of
vitamin D3 supplementation in ambulatory adults [19].
Recruitment began from December 2006 to March 2007
and the study was completed in June 2007. The partici-
pants were randomly assigned using a computer-generated
randomization sequence to receive either 50μg/d of vitamin
D3 or matching placebo. Each subject was sequentially
assigned a number upon study entry and the investigators
dispensed the corresponding sequentially numbered con-
tainer of study medication to the subject. All participants
and investigators were blinded throughout the study except
for the research pharmacist and the statistician. Neither the
statistician nor the research pharmacist had any contact with
study participants. Eligible subjects underwent a baseline
medical history, height and weight measurements, and
blood tests. Subjects were seen at 6-weeks and 12-weeks
postrandomization. Blood was collected again at the 12-
week visit. 25(OH)D and the levels of 10 diﬀerent cytokines
(IL-2, 4, 5, 6, 8, 10, 13, GM-CSF, IFN-γ,T N F - α)w e r e
measured in the serum of participants at baseline and the
ﬁnal visit.
2.3. Laboratory Tests. Serum samples were analyzed by
Ray Biotech Quantibody Human Th1/Th2 Array 1 kit
using glass-chip-based multiplexed sandwich ELISA system.
The signals are detected using ﬂuorescence-based detection
method. Baseline and study-end serum samples were ana-
lyzed in one assay. The well-to-well CV is <20%.
Serum 25(OH)D was measured by a radio-receptor
assay from DiaSiorin, Inc (Stillwater, MN). The intraassay
variability in our laboratory is 4.1% and interassay vari-
ability is 7.0%. Our laboratory participates in the inter-
national Vitamin D External Quality Assessment Program
(http://www.deqas.org/). Vitamin D3 content was analyzed
in an independent laboratory (Vitamin D, Skin, and Bone
Research Laboratory, Department of Medicine, Boston Uni-
versity School of Medicine, Boston, MA).International Journal of Endocrinology 3
297 assessed for eligibility
135 excluded
74 did not meet inclusion criteria
61 refused to participate
162 randomized
84 randomized to receive
50 mcg/d of vitamin D3
78 randomized to receive placebo
6 discontinued 8 discontinued
78 analyzed at endpoint 70 analyzed at endpoint
Figure 1: Epidemiology and Infection, Volume 137, Issue 3, 2009 “A randomized controlled trial of vitamin D3 supplementation for the
prevention of symptomatic upper respiratory tract infections” by John Aloia. c  2009 Cambridge University Press.
2.4. Statistical Analysis. The signed rank test was used to
assess the median percent change of each cytokine level
within the active vitamin D or placebo group during the
12-week period. The rank-sum test was used to compare
median percent change between the active vitamin D and
placebo groups. An estimate of the diﬀerence of the two
medians (active vitamin D-placebo) and the corresponding
95% conﬁdence interval was calculated using the software
Conﬁdence Interval Analysis (CIA), Version 2.0.0. We also
pooled both groups together and calculated percent changes
in 25(OH)Dover 12 weeks. Spearman correlations werethen
calculated between these percent changes in 25(OH)D and
percent changes of each cytokine level. Since analysis was
done for 10 cytokines, we used the Bonferroni adjustment
and results were considered signiﬁcant at the P = .05/10 =
.005 level of signiﬁcance. For all calculations (except for con-
ﬁdence interval analysis), we utilized SAS 9.2 for Windows,
SAS Institute Inc., Cary, N.C.
3. Results
3.1. Baseline Characteristics. The baseline characteristics and
laboratory values of the study population are summarized in
Table 1 [19]. T-tests comparing active to placebo patients at
baseline did not reveal any diﬀerences between the groups.
The baseline 25(OH)D levels ranged from 16 to 156nmol/L
with a mean level of 63.7 ± 28.7nmol/L in the study
population. At baseline, 23% of the active patients exceeded
75nmol/L.
3.2. Adherence. Adherence (deﬁned as the ratio of the
number of pills consumed to the number of days in the
study) ranged from 59% to 100%. Mean compliance was
94% ± 9%. Adherence did not signiﬁcantly diﬀer between
the active and placebo groups.
3.3. Cytokine Levels. There were no statistically signiﬁcant
diﬀerences between the two groups with respect to median
percentdiﬀerencesforeachcytokine.Theonlyexceptionwas
for IL-10, where the percent change for the active vitamin
Dg r o u pw a s−70.4% versus only −49.6% for placebo (P =
.02). However, the Bonferroni adjustment would need to be
removed in order to obtain signiﬁcance at P<. 05.
In the active vitamin D group, we found a signiﬁcant
median percent decline in levels of GM-CSF (−62.9%, P<
.0001), IFN-γ (−38.9%, P<. 0001), IL-4 (−50.8%, P =
.001), IL-8 (−48.4%, P<. 0001), and IL-10 (−70.4%, P<
.0001). In the placebo group, there were signiﬁcant declines
(butslightlysmallercomparedtotheactivevitaminDgroup)
for GM-CSF (−53.2%, P = .0007) and IFN-γ (−34.4%,
P = .0011). For each cytokine, there was no signiﬁcant
diﬀerence in the rate of decline between the two groups.
25(OH)DlevelsincreasedintheactivevitaminDgroupfrom
am e a no f6 4 .3 ± 25.4nmol/L to 88.5 ± 23.2nmol/L. At the
end of the study, 73% of the active vitamin D group patients
exceeded 75nmol/L. Spearman correlation analysis showed
no signiﬁcant correlations for any of the 10 cytokines: the
strongest correlations were r =− 0.096 (P = .30) for IL-8
and r = 0.079 (P = .39) for IL-5.4 International Journal of Endocrinology
Table 1: Baseline characteristics of study participants. There were no signiﬁcant diﬀerences between the study groups at baseline.
Characteristic Active (n = 78) Placebo (n = 70)
∗Age, y 59.3 ±13.05 8 .1 ±13.4
BMI, kg/m2 26.1 ±4.52 6 .6 ±4.1
∗∗Male 17 (21.8%) 13 (18.6%)
Female 61 (78.2%) 57 (81.4%)
Race
Caucasian 70 (89.7%) 61 (87.1%)
African American 3 (3.8%) 3 (4.3%)
Asian 2 (2.6%) 6 (8.6%)
Other 3 (3.8%) 0 (0.0%)
∗25-OHD, nmol/L 64.3 ±25.46 3 .0 ±25.8
PTH, pg/mL 29.2 ±13.62 8 .4 ±12.6
History of tobacco use 26 (33.3%) 28 (40%)
History of asthma 6 (7.7%) 2 (2.9%)
History of COPD 3 (3.8%) 2 (2.9%)
Received ﬂu vaccine 44 (56.4%) 45 (64.3%)
Dietary calcium intake (mg/d) 762.8 ±375.7 854.6 ±518.6
Dietary vitamin D intake (IU/d) 147.3 ±182.3 168 ±146.5
∗Values are expressed as mean ±SD.
∗∗Values are expressed as n (%).
Epidemiology and Infection, see [19] c  2009 Cambridge University Press.
Cytokine results as described above are summarized in
Table 2.W ep r o v i d ei nT a b l e3, for each cytokine, the
diﬀerence of the median percent change (Active vitamin D-
Placebo) and the corresponding 95% conﬁdence interval.
We note that for nine of the ten cytokines, the estimated
diﬀerence of medians between the two groups was within
±10%, which would likely represent a clinically insigniﬁcant
diﬀerence. The only exception was for cytokine IL-10, where
the group diﬀerence was statistically signiﬁcant (P = .02
before the Bonferroni adjustment as previously mentioned).
We also considered a subanalysis consisting of placebo group
who are vitamin D insuﬃcient (<75nmol/l) both at the start
and the end of the study versus. active vitamin D group who
were insuﬃcient at the start and became suﬃcient at the end
of the study. These “modiﬁed” placebo and active vitamin D
groups consisted of 33 and 30 patients, respectively. When
we repeat the analysis done in Table 2, the rank sum P-
values (comparing active vitamin D with placebo) are all
nonsigniﬁcant, with P>. 30 for all 10 parameters.
3.4. Adverse Events. A total of 72 adverse events were
reported in the study over 3 months, 38 in the active vitamin
Dg r o u pa n d3 4i nt h ep l a c e b og r o u p ,P = .99. There was no
signiﬁcant diﬀerence in the adverse events between the study
groups. There were 3 serious adverse events, one in the active
vitamin D group and two in the placebo group. None of the
serious adverse events were considered to be related to the
study medication. There were no episodes of nephrolithiasis
or hypercalcemia.
4. Discussion
The present study did not show an eﬀect of vitamin
D3 supplementation on the circulating levels of certain
cytokines. We predicted that the levels of IL-2, 6, IFN-γ,
TNF-α, and GM-CSF will decrease under the inﬂuence of
vitamin D, while the levels of IL-4, 5, 10, and 13 were
expected to rise [23–25]. We did not ﬁnd that cytokine levels
or changes in cytokine levels were responsive to vitamin
D supplementation or related to serum 25(OH)D levels.
However,thereisaccumulatingevidencethatvitaminDdoes
signiﬁcantly alter the immune system [26]. In gene chip
experiments, the active form of vitamin D has been shown
to downregulate gene expression of T-helper 1 cells, at the
same time up regulating gene expression of T-helper 2 cells
[24]. Decreased production of INF-gamma and IL-12 by T-
helper 1 cells, and induction of regulatory T cells inﬂuenced
by 1,25(OH)2D regulates immune responses to infections
[23]. 1,25(OH)2D has been shown to induce the expression
of IL-10 by CD40/IL-4-activated B-cells by binding of the
VDR to the promoter of IL-10 [25].
The role of 1,25(OH)2D in innate and adaptive immu-
nity has also been demonstrated in vivo. Following in vivo
stimulation of murine dendritic cells by lipopolysaccharide
(bacterial-derivedendotoxin),theywerefoundtoproduce1-
alpha-hydroxylase, resulting in production of active form of
vitamin D [27]. Hansdottir et al. proposed a mechanism by
which vitamin D plays a role in host defense by demonstrat-
ingtheconversionofinactivevitaminD(25(OH)D)toactive
1,25(OH)2D by enzyme 1alpha-hydroxylase in respiratory
epithelial cells [28]. Impaired production of 1,25(OH)2D
due to low-circulating 25(OH)D levels results in inhibition
of VDR-dependent innate immune response [8].
1,25(OH)2DinhibitstheproductionofIL-12,IFN-γ and
promotes production of IL-4 following endotoxin stimula-
tion in rats [24]. Human B-cells experiments demonstrated
the ability of 1,25(OH)2D to induce the expression ofInternational Journal of Endocrinology 5
Table 2: Laboratory values.
Active (n = 63) Placebo (n = 57)
Rank-sum
P-value Cytokine Median baseline
value (in pg/ml)
Median percent
change (12
weeks)
P-value
(signed-rank
test)
Median baseline
value (in pg/ml)
Median percent
change (12
weeks)
P-value
(signed-rank
test)
GM-CSF 5.91 −63.0 <.0001 4.78 −53.2 .0007 .53
IFN-γ 130.8 −38.9 <.0001 115.2 −34.4 .0011 .41
IL-2 2.13 −17.6 .70 2.15 −23.8. 5 2 . 9 6
IL-4 6.10 −50.8 .001 8.26 −39.4 .006 .47
IL-5 4.88 −8.32 .49 4.53 −30.0. 6 6 . 5 0
IL-6 2.19 −43.2 .37 2.75 −52.9 .0963 .61
IL-8 16.3 −48.4 <.0001 24.1 −33.0 .0210 .21
IL-10 6.82 −70.4 <.0001 5.12 −49.6 .0401 .02
IL-13 0.604 −59.4 .0104 0.500 −14.4. 2 2 . 2 1
TNF-α 5.64 −12.0 .21 7.60 −21.8 .0542 .64
Table 3: Median Diﬀerence of Percent Changes (Active vitamin D-Placebo).
Cytokine Diﬀerence of MedianPercent
Change (Active vitamin D-Placebo) 95% CI of Diﬀerence of Medians
GM-CSF −3.86% (−19.9%, 9.69%)
IFN-γ −5.24% (−18.6%, 8.47%)
IL-2 0.21% (−31.4%, 26.9%)
IL-4 −5.59% (−27.2%, 9.10%)
IL-5 8.62% (−17.6%, 41.0%)
IL-6 4.14% (−12.5%, 24.4%)
IL-8 −9.43% (−27.2%, 5.15%)
IL-10 −17.0% (−38.6%, −1.15%)
IL-13 −9.08% (−48.7%, 4.71%)
TNF-α −5.67% (−38.1%, 23.9%)
chemokine (C-C motif) receptor 10 (CCR10), which plays
an important role in the mucosal immune system [29].
In patients with severe congenital neutropenia,
1,25(OH)2D induced the expression of the human cathe-
licidinantimicrobialpeptide18precursorproteininmyeloid
precursors [30]. The process of activation of vitamin D in
human tracheobronchial cells causes upregulation of
cathelicidin antimicrobial peptide gene and the TLR
coreceptor CD14, contributing to innate immunity in the
lungs [28].
Data on vitamin D regulating serum cytokines in
placebo-controlled clinical trials is very limited. In a 6-
month double-blind, placebo-controlled, randomized trial
in vitamin D-insuﬃcient patients with MS, 25μg (1000 IU)
vitamin D signiﬁcantly increased serum levels of TGF-beta
1, while having no eﬀect on TNF-α,I F N - γ,a n dI L - 1 3[ 31].
Another randomized, placebo-controlled clinical trial in 123
CHF patients demonstrated that 50μg (2000 IU) of vitamin
D, administered for 9 months, increased median serum
levels of anti-inﬂammatory IL-10 by 43%, and suppressed
the levels of proinﬂammatory TNF-α [16]. The median
baseline 25(OH)D levels in that trial were signiﬁcantly lower
compared to our study: 35.87nmol/l in vitamin D group and
38.09nmol/l in the placebo group. Seasonal diﬀerences in
cytokine levelswereobserved byStewartet al. among healthy
controls, who noted lower winter levels of IL-4, IL-10 and
TNF-α, and a winter excess of IFN-γ [32]. These ﬁndings
further support the hypothesis that seasonal diﬀerences in
vitamin D inﬂuence the levels of cytokines and may help
explain our ﬁnding of declining serum cytokines levels
during winter months in the active vitamin D, as well as the
control group.
The strengths of this study include the high compliance
rate of medication intake (94%) and low-dropout rate. The
mean 25(OH)D level of the subjects at baseline (63.7 ±
28.7nmol/L) was in accord with the mean 25(OH)D
level in NHANES III (64.8nmol/L) measured during the
winter [33]. Our laboratory participates in the international
Vitamin D External Quality Assessment Program which
ensures the analytical reliability of 25(OH)D assays. Vitamin
D content in the tablets was veriﬁed by an independent
laboratory.
We recognize that this study has several limitations.
50μg/day may not be enough to stimulate innate immunity,6 International Journal of Endocrinology
and/or the length of the study may not have been suﬃcient
to observe an eﬀect. Another reason why we may not
have observed a beneﬁt is that the mean 25(OH)D level
at the beginning of the study was not that low but it
was not diﬀerent from the average level seen in NHANES
III. Vitamin D repletion in subjects who were deﬁcient at
baselinemayhaveresultedinmeaningfulchangesincytokine
levels however, our study was not designed to address this
question. 73% of patients in the vitamin D group achieved
25(OH)D levels greater than 75nmol/L but the diﬀerence
between baseline and end-of-study levels may not be enough
to confer a beneﬁt.
Although there is an increasing amount of evidence from
animal experiments and human case-control studies that
demonstratethe role of vitaminD in host defense,additional
randomized clinical trials are needed [34].
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